Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.21
Nov 13 • 3:59 PM ET Dollar change-0.01 Percentage change(-0.82%)
Aftermarket Close
1.32
Aftermarket • 7:44 PM ET Dollar change+0.11 Percentage change(9.09%)
Index
-
Market Cap
8.34M
Enterprise Value
1.47M
Income
-15.11M
Sales
0.00M
Book/sh
0.61
Cash/sh
2.00
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
16
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.97
P/C
0.61
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.96
Current Ratio
4.96
Debt/Eq
1.63
LT Debt/Eq
1.63
Option/Short
No / Yes
EPS (ttm)
-4.44
EPS next Y
-2.29
EPS next Q
-0.63
EPS this Y
86.09%
EPS next Y
-66.91%
EPS next 5Y
44.16%
EPS past 3/5Y
89.18% 38.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
45.29%
Sales Y/Y TTM
-
EPS Q/Q
90.64%
Sales Q/Q
-
Insider Own
39.39%
Insider Trans
10.09%
Inst Own
35.73%
Inst Trans
19.39%
ROA
-103.47%
ROE
-763.32%
ROIC
-135.80%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-8.77%
SMA50
-21.15%
SMA200
-59.32%
Trades
Shs Outstand
6.89M
Shs Float
4.18M
52W High
36.00 -96.64%
52W Low
1.00 21.00%
Volatility
15.49% 15.72%
ATR (14)
0.20
RSI (14)
41.53
Beta
0.79
Rel Volume
0.39
Avg Volume
81.84K
Volume
31,548
Perf Week
-11.03%
Perf Month
12.04%
Perf Quarter
-63.47%
Perf Half Y
-63.17%
Perf YTD
-96.33%
Perf Year
-92.51%
Perf 3Y
-92.88%
Perf 5Y
-99.45%
Perf 10Y
-
Prev Close
1.22
Price
1.21
Change %
-0.82%
Consensus
Buy
Avg. Price Target
$25.50
Implied Upside
+2,007.4%
Analysts2incl. previous ratings
Rating Distribution1 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 20, 2026Initiated
GGuggenheim
Buy$9+643.8%
Jan 29, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Middleton Fred ADirectorJun 25 '26Buy0.80248,972199,9991,063,272Jun 29 08:45 AM
CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
CEO & DirectorDr. A. Rachel Leheny Ph.D.
Chief Business Officer & Vice Chairman of the BoardMr. Eric W. Roberts
Chief Medical OfficerDr. Sudarshan Hebbar M.D.
M.B.A.Mr. Michael J. Dunn B.A.
Co-Founder and Scientific AdvisorDr. Anjana Rao Ph.D.